The short version of tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
== Early life == Baldwin was born on February 27, 1962, in Winnetka, Illinois, and studied at New Trier Township High School in east Winnetka. Raised in the Chicago area, Baldwin played hockey as a youth.
However, the advent of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmacoeconomic concerns because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. This factor has been particularly relevant since many biological medications are used to treat chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of otherwise untreatable cancer during the remainder of life. The cost of treatment with a typical monoclonal antibody therapy for relatively common indications is generally in the range of €7,000–14,000 per patient per year. Older patients who receive biologic therapy for diseases such as rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis are at increased risk for life-threatening infection, adverse cardiovascular events, and malignancy. The first such substance approved for therapeutic use was biosynthetic "human" insulin made via recombinant DNA. Sometimes referred to as rHI, under the trade name Humulin, was developed by Genentech, but licensed to Eli Lilly and Company, who manufactured and marketed it starting in 1982. Major kinds of biopharmaceuticals include:
(2026) reconstruct the environment of Pleistocene gazelles and Persian fallow deer from the Mughr el-Hamamah site (Jordan) on the basis of isotopic analysis of their teeth, interpret their findings as indicative of conditions that were favorable for human occupations during a humid phase of the Last Glacial cycle, and estimate that the hunting area of Early Upper Paleolithic humans from the site covered ∼36 square kilometers. García-Morato et al. (2026) review the fossil record of small-bodied mammals from Middle to Later Stone Age sites in South Africa, and report evidence of impact of site-specific ecological factors on the composition of the studied assemblages. Sawada et al. (2026) interpret burned bone fragments from the terminal Paleolithic strafa from the Fukui Cave (Japan) as more likely to be evidence of human exploitation of medium-sized artiodactyls than evidene of exploitation of large mammals that became extinct in the Pleistocene. Evidence indicating that deposition of sediments preserving bones of mammals (mostly mammoths) at The Mammoth Site (South Dakota, United States) happened during Marine Isotope Stages 6 and 7 is presented by Mahan et al. (2026). Pym et al. (2026) reconstruct changes of late Pleistocene megafaunal populations from the Isthmus of Panama on the basis of the study of spores of coprophilous fungi from sediments of the La Yeguada lake, providing evidence of three distinct phases of decline and recovery coinciding with shifts in vegetation composition. Asevedo et al.
== Target == Do6a primarily targets Pickpocket/Balboa (Ppk/Bba or Ppk1/Ppk26) ion channels that are evenly distributed on the dendrites of class IV dendritic arborizing (cIV da) neurons in the peripheral nervous system of fruit fly larvae. cIV da neurons are responsible specifically for nociception from mechanical stimuli and heat, unlike cI, cII cIII that respond to other sensory input, like proprioception or gentle touch. These neurons have highly complex dendritic trees and blocking their synaptic output significantly reduces behavioral nociceptive responses (e.g. rolling) in larvae. Do6a appears to target exclusively insect nociceptors, likely due to the parasitic reproduction cycle of the species requiring good protection against other insects. Other peptides in the venom (e.g. Do10a and Do13a) affect pain receptors in mammals. Expression of both Ppk and Bba forming a heteromeric channel complex in cIV da neurons are necessary for nociception from Do6a. Ppk/Bba belong to Degenerin/Epithelial (DEG/ENaC) protein family and respond specifically to mechanical nociception and not noxious heat. Gating of these channels is still not entirely understood. While their activation upon harsh mechanical pressure may suggest a mechanosensitive nature of these channels, peptides like Do6a and Vulnusin have been shown to activate Ppk1/Ppk26 without a presence of a mechanical stimulus, pointing towards ligand-gating instead.
== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.
Sources: en.wikipedia.org
Kiggans announced on January 7, 2024, that she would run for reelection in the 2024 election—a race targeted by the Democratic Congressional Campaign Committee. In June 2024, she participated in a rally with former president Donald Trump and incumbent governor Glenn Youngkin in Chesapeake after the first presidential debate. Kiggans faced Democratic nominee Missy Cotter Smasal, a fellow Navy veteran. Kiggans campaigned on support for a Mexico–United States border wall and lowering inflation occurring under the Biden administration. The Cook Political Report rated the election as "Lean Republican" by November 1, 2024. Kiggans defeated Smasal by a 4-point margin in the general election, larger than her 3-point margin in the 2022 election.
== Bibliography == Bogle, James and Joanna. (1990). A Heart for Europe: The Lives of Emperor Charles and Empress Zita of Austria-Hungary, Fowler Wright, 1990, ISBN 0-85244-173-8 Brook-Shepherd, Gordon. (1991). The Last Empress: The Life and Times of Zita of Austria-Hungary 1893–1989. Harper-Collins. ISBN 0-00-215861-2 Harding, Bertita. (1939). Imperial Twilight: The Story of Karl and Zita of Hungary. Bobbs-Merrill Company Publishers. ASIN: B000J0DDQO (in German) Bernhard A. Macek: Kaiser Karl I. Der letzte Kaiser Österreichs. Ein biografischer Bilderbogen, Sutton Verlag, Erfurt 2012, ISBN 978-3-9540-0076-0 (in French) Debris, Cyrille. (2013). Zita, Portrait intime d'une imperatrice. Cerf, Paris, 2013, ISBN 978-2-204-10085-4
The control of enzymatic browning has always been a challenge for the food industry. A variety of approaches are used to prevent or slow down enzymatic browning of foods, each method aimed at targeting specific steps of the chemical reaction. The different types of enzymatic browning control can be classified into two large groups: physical and chemical. Usually, multiple methods are used. The use of sulfites (powerful anti-browning chemicals) have been reconsidered due to the potential hazards that it causes along with its activity. Much research has been conducted regarding the exact types of control mechanisms that take place when confronted with the enzymatic process. Besides prevention, control over browning also includes measures intended to recover the food color after its browning. For instance, ion exchange filtration or ultrafiltration can be used in winemaking to remove the brown color sediments in the solution.
===== Impact on impoverished communities ===== In countries where cocaine is illicitly produced, an intermediate product known as cocaine paste—often referred to as "poor man's cocaine"—is frequently smoked in impoverished communities. This substance is favored in these areas primarily because it is inexpensive and more accessible than refined cocaine. However, the use of cocaine paste poses severe health risks. During its production, various toxic chemicals are used to extract coca alkaloids from the coca leaves. Many of these hazardous substances, such as solvents and acids, remain in the paste after processing. When the paste is smoked, individuals are exposed not only to the addictive effects of the drug itself but also to the dangerous residual chemicals, which can cause significant harm to the lungs, nervous system, and overall health. This combination of affordability, accessibility, and toxicity makes cocaine paste particularly damaging to vulnerable populations in cocaine-producing regions.
Sources: en.wikipedia.org
== Chemistry == Pure anhydrous caffeine is a bitter-tasting, white, odorless powder with a melting point of 235–238 °C. Caffeine is moderately soluble in water at room temperature (2 g/100 mL), but quickly soluble in boiling water (66 g/100 mL). It is also moderately soluble in ethanol (1.5 g/100 mL). It is weakly basic (pKa of conjugate acid = ~0.6) requiring strong acid to protonate it. Caffeine does not contain any stereogenic centers and hence is classified as an achiral molecule. The xanthine core of caffeine contains two fused rings, a pyrimidinedione and imidazole. The pyrimidinedione in turn contains two amide functional groups that exist predominantly in a zwitterionic resonance the location from which the nitrogen atoms are double bonded to their adjacent amide carbons atoms. Hence all six of the atoms within the pyrimidinedione ring system are sp2 hybridized and planar. The imidazole ring also has a resonance. Therefore, the fused 5,6 ring core of caffeine contains a total of ten pi electrons and hence according to Hückel's rule is aromatic. Caffeine can be easily protonated to form corresponding caffeinium. This cationic form is the main way in which caffeine exists in acidic solutions.
== Veterinary use == Benzodiazepines are used in veterinary practice in the treatment of various disorders and conditions. As in humans, they are used in the first-line management of seizures, status epilepticus, and tetanus, and as maintenance therapy in epilepsy (in particular, in cats). They are widely used in small and large animals (including horses, swine, cattle and exotic and wild animals) for their anxiolytic and sedative effects, as pre-medication before surgery, for induction of anesthesia and as adjuncts to anesthesia.
=== Mumps === Mumps is another viral disease that was once very common, especially during childhood. If mumps is acquired by a male who is past puberty, a possible complication is bilateral orchitis, which can in some cases lead to sterility.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。